AZD6738 First Time in Patient Multiple Ascending Dose Study
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients
with relapsed/refractory CLL, PLL or B cell lymphoma.
In Part B to investigate the safety and tolerability of AZD6738 when given orally to patients
with prospectively identified 11q deleted or ATM deficient, relapsed/refractory CLL